# RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is an Asset Manager based in Tel Aviv, Israel.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Tel Aviv, Israel
- **Region:** Middle East
- **Address:** Tel Aviv, Israel
- **Founded:** 2009
- **Assets under management:** Undisclosed
- **Website:** redhillbio.com
- **LinkedIn:** https://www.linkedin.com/company/redhill-biopharma

## Regulatory record

- **Reports private funds:** No

## About

RedHill Biopharma Ltd. was founded in 2009 by Dror Ben-Asher, Ori Shilo, and others. The firm emerged as a specialty pharmaceutical company targeting gastrointestinal diseases and infectious diseases, with a commercial-stage pipeline that includes both approved and development-stage therapies. The company's strategy centers on in-licensing and developing late-stage drug candidates with known mechanisms of action, reducing regulatory risk. RedHill's marketed portfolio includes Movelat (for musculoskeletal pain) and Talicia (for Helicobacter pylori infection); its pipeline includes opaganib and RHB-107, which were evaluated in COVID-19 trials. Geographically, operations span Israel and the US via its Raleigh, NC base. The firm has partnerships with companies like SRL Pharma (per public filings, 2023). RedHill trades on the Nasdaq (RDHL) and Tel Aviv Stock Exchange. Team size is not publicly disclosed, but the firm maintains a lean structure typical of specialty pharma. In April 2023, the company received a US patent for opaganib in gastroenterology indications. The firm's most distinctive structural characteristic is its hybrid operating company model: it is a commercial-stage biopharma, not a venture capital firm, generating revenue from product sales rather than management fees. This aligns incentives directly with drug commercialization milestones.

## Sectors

- Biopharma
- Gastroenterology
- Infectious Disease

## Offices

- Raleigh, NC, United States

## People

- Dror Ben-Asher — Executive Chairman
- Guy Goldberg — Chief Executive Officer
- Rick Scruggs — Chief Financial Officer

## Questions

### What is RedHill Biopharma's business model?

RedHill is a specialty pharmaceutical company that develops and commercializes late-stage drug candidates for gastrointestinal and infectious diseases. It generates revenue from product sales (e.g., Talicia for H. pylori) and uses that income to fund ongoing R&D. This self-sustaining model is unusual among developmental biotechs.

### Who founded RedHill Biopharma?

RedHill was founded in 2009 by Dror Ben-Asher and Ori Shilo. Ben-Asher serves as Executive Chairman and is the company's longest-serving leader.

### What are RedHill's key therapeutic areas?

The company focuses on gastrointestinal diseases (e.g., H. pylori infection, gastroparesis) and infectious diseases. Its marketed drugs include Talicia (H. pylori) and Movelat (musculoskeletal pain). Pipeline candidates include opaganib for COVID-19 and other conditions.

### Does RedHill have commercial-stage revenue?

Yes. RedHill has two FDA-approved products — Talicia and Movelat — which generate revenue. This distinguishes it from many development-stage biotechs that lack commercial income.

### Is RedHill publicly traded?

Yes. RedHill Biopharma is listed on Nasdaq under the ticker RDHL and also trades on the Tel Aviv Stock Exchange. This provides public market visibility and access to capital.

### What is RedHill's geographic presence?

The company is headquartered in Tel Aviv, Israel, with operational offices in Raleigh, North Carolina. It markets products in the US and has partnerships in other regions.

### How has RedHill funded its R&D?

RedHill funds its R&D primarily through product sales and public equity offerings, rather than venture capital or private equity. This non-dilutive revenue model supports ongoing clinical trials without external investment.

## Related profiles

- [ICZOOM Group Inc.](https://altss.com/profile/iczoom-group-inc)
- [MacKenzie Realty Capital](https://altss.com/profile/mackenzie-realty-capital-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/redhill-biopharma-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology
